Management of antiplatelet therapy for minimization of bleeding risk before cardiac surgery

Pharmacotherapy

Volumn 26, Issue 11, 2006, Pages 1616-1625

  Weant, Kyle A ^a   Flynn, Jeremy F ^b   Akers, Wendell S ^b,c  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c Division of Pharmacy Practice and Science   (United States)

Author keywords

Antifibrinolytics; Antiplatelet; Aspirin; Bleeding; CABG; Cardiac surgery; Clopidogrel; Coronary artery bypass grafting; Glycoprotein IIb IIIa inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LYSINE DERIVATIVE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TICLOPIDINE; TRANEXAMIC ACID;

BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LABORATORY TEST; NEUTROPENIA; PHARMACODYNAMICS; POINT OF CARE TESTING; REVIEW; RISK ASSESSMENT; THROMBOCYTE FUNCTION; THROMBOCYTOPENIC PURPURA;

ADENOSINE DIPHOSPHATE; ASPIRIN; BLOOD LOSS, SURGICAL; CORONARY ARTERY BYPASS; CORONARY THROMBOSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 33750697029     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.11.1616     Document Type: Review

References (80)

1. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery. Available from http://www.americanheart.org. Accessed December 14, 2005.
2. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. AHA 2006 statistical update: heart disease and stroke statistics. Available from http://www.americanheart.org. Accessed March 12, 2006.
3. Murphy GJ, Angelini GD. Side effects of cardiopulmonary bypass. J Card Surg 2004;19:481-8.
4. McCusker K, Lee S. Postcardiopulmonary bypass bleeding: an introductory review. J Extra Corpor Technol 1999;31:23-6.
5. Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996;82:13-21.
6. Dacey LJ, Munoz JJ, Baribeau YR, et al. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England cardiovascular disease study group. Arch Surg 1998;133:442-7.
7. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996;111:1037-46.
8. Lee LY, DeBois W, Krieger KH, et al. The effects of platelet inhibitors on blood use in cardiac surgery. Perfusion 2002;17:33-7.
9. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995;9:168-73.
10. Steinhubl SR. Antiplatelet agents in cardiology: the choice of therapy. Ann Thorac Surg 2000;70:S3-8.
11. Sellke FW, DiMaio JM, Caplan LR, et al. American Heart Association scientific statement: comparing on-pump and off-pump coronary artery bypass grafting. Circulation 2005;111:2858-64.
12. Roberts LJ, Morrow JD. Analgesic-antipyretic agents. In: Hardman JG, Limbird LE, Goodman LS, Gilman A, eds. Goodman & Gilmans the pharmacologic basis of therapeutics. New York: McGraw-Hill, 2001:687-703.
13. Ferraris VA, Ferraris SP, Lough FC, Berry WR. Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Ann Thorac Surg 1988;45:71-4.
14. Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson WG. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs cooperative study on antiplatelet therapy. J Am Coll Cardiol 1990;15:15-20.
15. Bashein G, Nessly ML, Rice AL, Counts RB, Misbach GA. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med 1991;151:89-93.
16. Tuman KJ, McCarthy RJ, O'Connor CJ, McCarthy WE, Ivankovich A. Aspirin does not increase allogeneic blood transfusion in reoperative coronary artery surgery. Anesth Analg 1996;83:1178-84.
17. Stein PD, Dalen JE, Goldman S, Theroux P. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 2001;119:278S-82.
18. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery: a placebo-controlled, randomized study. Circulation 1991;83:1526-33.
19. Ferraris VA, Ferraris SP, Mliterno DJ, et al. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization. Ann Thorac Surg 2005;79:454-61.
20. Burger W, Chemnitius J-M, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med 2005;257:399-414.
21. Bidstrup BP, Hunt BJ, Sheikh S, Parratt RN, Bidstrup JM, Sapsford RN. Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting. Ann Thorac Surg 2000;69:541-7.
22. Landymore RW, Murphy JT, Lummis H, Carter C. The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations. Euro J Cardiothorac Surg 1997;11:798-800.
23. Munoz JJ, Birkmeyer NJO, Birkmeyer JD, O'Conner GT, Dacey LJ. Is ε-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation 1999;99:81-9.
24. Nielsen HJ, Reimert C, Pedersen AN, et al. Leucocyte-derived bioactive substances in fresh frozen plasma. Br J Anaesth 1997;78:548-52.
25. Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004;44:1143-8.
26. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
27. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systemic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8.
28. Despotis GJ, Goodnough LT. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann Thorac Surg 2000;70(2 suppl):S20-32.
29. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 study. Circulation 2005;111:2099-106.
30. Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006;47:939-43.
31. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Circulation 2005;112:2946-50.
32. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001;29:2271-5.
33. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-7.
34. Fox KAA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome. The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation 2004;110:1202-8.
35. Bristol-Myers Squibb, sanofi-aventis. Plavix (clopidogrel bisulfate) prescribing information. Available from http://www.plavix.com. Accessed April 22, 2006.
36. Lindvall G, Sartipy U, Van der Linden J. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting. Ann Thorac Surg 2005;80:922-7.
37. Halkos ME, Levy JH, Chen E, et al. Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery. Ann Thorac Surg 2005;79:1303-6.
38. Vanek T, Straka Z, Hrabak J, Jares M, Brucek PJ, Votara J. Use of recombinant activated factor VII in cardiac surgery for an effective treatment of severe intractable bleeding. Jpn Heart J 2004;45:855-60.
39. Oh JJ, Akers WS, Lewis D, Ramaiah C, Flynn JD. Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 2006;26:569-77.
40. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA 1999;281:1407-14.
41. Tcheng JE. Differences among the patenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. Am J Cardiol 1999;83(9 suppl 1):7E-11.
42. Alton KB, Kosoglou T, Baker S, Affrime MB, Cayen MN, Patrick JE. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 1998;20:307-23.
43. Alvarez JM. Emergency, coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab. J Thorac Cardiovasc Surg 1998;115:472-3.
44. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
45. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 1997;349:1422-8.
46. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
47. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
48. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM. Vascular access site complications after percutaneous coronary intervention with abciximab in the evaluation of c7E3 for the prevention of ischemic complications (EPIC) trial. Am J Cardiol 1998;81:36-40.
49. Silvestry SC, Smith PK. Current status of cardiac surgery in abciximab-treated patients. Ann Thorac Surg 2000;70:512-19.
50. Singh M, Nuttall GA, Ballman KV, et al. Effect of abciximab on the outcome of emergency coronary artery bypass grafting after failed percutaneous coronary intervention. Mayo Clin Proc 2001;76:784-8.
51. Korte T, Jung W, Schlippert U, et al. Prospective evaluation of shoulder-related problems in patients with pectoral cardioverter-defibrillator implantation. Am Heart J 1998;135:577-83.
52. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Ann Thorac Surg 2000;70:866-71.
53. Duke C, Gammie JS. Surgical implications of platelet glycoprotein IIb-IIIa inhibition. J Thorac Cardiovasc Surg 1998;116:1083-4.
54. Bizzarri F, Scolletta S, Tucci E, et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001;122:1181-5.
55. Gammie JS, Zenati M, Kormos RL, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998;65:465-9.
56. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
57. Madan M, Blankenship JC, Berkowitz SD. Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. Curr Opin Hematol 1999;6:334-41.
58. Lemmer JH Jr, Metzdorff MT, Krause AH Jr, Martin MA, Okies JE, Hill JG. Emergency coronary artery bypass graft surgery in abciximab-treated patients. Ann Thorac Surg 2000;69:90-5.
59. Juergens CP, Yeung AC, Oesterle SN. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol 1997;80:74-5.
60. Lemmer JH Jr. Clinical experience in coronary artery bypass surgery for abciximab-treated patients. Ann Thorac Surg 2000;70(2 suppl):S33-7.
61. Despotis GJ, Gravelee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999;91:1122-51.
62. Harder S, Klinkhardt U, Alarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004;43:963-81.
63. Li YF, Spencer FA, Becker RC. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition. Am Heart J 2002;143:725-32.
64. Kleiman NS. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am Heart J 1999;138:263-75.
65. Kereiakes DJ. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery [letter]. Am J Cardiol 1998;81:373.
66. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-72.
67. Primack C, Walenga JM, Koza MJ, Shankey TV, Pifarre R. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Ann Thorac Surg 1996;61:1188-93.
68. Shigeta O, Kojima H, Jikuya T, et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 1997;96:569-74.
69. Dorman BH, Spinale FG, Bailey MK, Kratz JM, Roy RC. Identification of patients at risk for excessive blood loss during coronary artery bypass surgery: thromboelastography versus coagulation screen. Anesth Analg 1993;76:694-700.
70. Ereth MH, Nuttall GA, Klindworth JT, et al. Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg 1997;85:259-64.
71. Gravlee GP, Arora S, Lavender SW, et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surgery 1994;58:216-21.
72. Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standing coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993;7:410-15.
73. Gelb AB, Roath RI, Levin J, et al. Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding. Am J Clin Pathol 1996;106:87-99.
74. Murray D, Pennell B, Olson J. Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. Transfusion 1999;39:56-62.
75. Despotis GJ, Santoro SA, Spitznagel E, et al. On-site prothrombin time, activated partial thromboplastin time and platelet count: a comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery. Anesthesiology 1994;80:338-51.
76. Khan NE, De Souza A, Mister R, et al. A randomized comparison of off-pump and on-pump multivessel coronary artery bypass surgery. N Engl J Med 2004;350:21-8.
77. Van Dijk D, Nierich AP, Jansen EW, et al. Early outcome after off-pump versus on-pump coronary bypass surgery: results from a randomized study. Circulation 2001;104:1761-6.
78. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump surgery in beating heart against cardioplegic arrest studies (BHACAS 1 and 2): a pooled analysis of two randomized controlled trials. Lancet 2002;359:1194-9.
79. Cartier R, Robitaille D. Thrombotic complications in beating heart operations. J Thorac Cardiovasc Surg 2001;121:920-2.
80. D'Ancona G, Donias HW, Karamanoukian RL, Bergsland J, Karamanoukian HL. OPCAB therapy survey: off-pump clopidogrel, aspirin or both therapy survey. Heart Surg Forum 2001;4:354-8.